Long-term prophylaxis for hereditary angioedema: Initial experiences with garadacimab and lanadelumab
Authors:
Open Access
- 30 August 2023
- journal article
- research article
- Published by Elsevier in Journal of Allergy and Clinical Immunology: Global
- Vol. 2 (4) , 100166
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Epidemiology, Management, and Treatment Access of Hereditary Angioedema in the Asia Pacific Region: Outcomes From an International SurveyThe Journal of Allergy and Clinical Immunology: In Practice, 2022
- Treatment of hereditary angioedema—single or multiple pathways to the rescueFrontiers in Allergy, 2022
- Prospective Study on the Efficacy and Impact of Cascade Screening and Evaluation of Hereditary Angioedema (CaSE-HAE)The Journal of Allergy and Clinical Immunology: In Practice, 2022
- The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and updateAllergy, 2022
- Impact of lanadelumab on health‐related quality of life in patients with hereditary angioedema in the HELP studyAllergy, 2020
- Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trialAllergy, 2020
- Current status of the management of hereditary angioedema in China: a patient-based, cross-sectional surveyEuropean Journal Of Dermatology, 2020
- Hereditary AngioedemaNew England Journal of Medicine, 2020
- [EFFICACY, PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF INTRAVENOUS C1 INHIBITOR FOR LONG-TERM PROPHYLAXIS AND TREATMENT OF BREAKTHROUGH ATTACKS IN JAPANESE SUBJECTS WITH HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY].2020